Skip to content
No results
  • About Us
  • Contact Us
  • Disclaimer
  • Event Venues
  • Events and Conferences
  • Home
  • Organizer Dashboard
  • Organizer Dashboard
  • Privacy Policy
  • Submit Organizer Form
  • Submit Organizer Form
  • Submit Venue Form
  • Submit Venue Form
  • Subscribe
  • Terms and Conditions
  • Venue Dashboard
  • Venue Dashboard
  • About Us
  • Contact Us
The Pharma Data

  • News
  • Press Releases
  • Research
  • Business
  • Regulatory
  • Events and Conferences
The Pharma Data
Ayrmid Pharma Ltd., a pioneering company in cell therapy
  • Business

RoslinCT & Ayrmid Pharma Plan Strategic Partnership for Omisirge® Manufacturing

  • The Pharma Data
  • March 12, 2025

RoslinCT and Ayrmid Pharma Ltd. Plan Strategic Partnership for Omisirge® Manufacturing Ayrmid Pharma Ltd., a pioneering company in cell therapy focused on transforming cells into powerful therapeutics, and RoslinCT, a…

Read MoreRoslinCT & Ayrmid Pharma Plan Strategic Partnership for Omisirge® Manufacturing
NationsBenefits® Partners with TS Emporium to Expand Access to Culturally Relevant Health Products
  • Press Releases

NationsBenefits® Partners with TS Emporium to Expand Access to Culturally Relevant Health Products

  • The Pharma Data
  • March 12, 2025

NationsBenefits® Partners with TS Emporium to Expand Access to Culturally Relevant Health Products NationsBenefits®, a leading provider of supplemental benefits and healthcare fintech solutions, has announced a strategic partnership with…

Read MoreNationsBenefits® Partners with TS Emporium to Expand Access to Culturally Relevant Health Products
Noramco Group Invests $25M in Halo Pharma for Sterile Injectables
  • News

Noramco Group Invests $25M in Halo Pharma for Sterile Injectables

  • The Pharma Data
  • March 11, 2025

Noramco Group Invests $25M in Halo Pharma for Sterile Injectables The Noramco Group Invests $25 Million in Halo Pharma’s Whippany Facility to Establish Sterile Injectable Manufacturing The Noramco Group, a…

Read MoreNoramco Group Invests $25M in Halo Pharma for Sterile Injectables
Care Access Acquires Brazil-Based Clinical Research Center CEMEC
  • Research

Care Access Acquires Brazil-Based Clinical Research Center CEMEC

  • The Pharma Data
  • March 11, 2025

Care Access Acquires Brazil-Based Clinical Research Center CEMEC Care Access, a globally recognized healthcare and clinical research organization, has announced the successful acquisition of Centro Multidisciplinar de Estudos Clínicos (CEMEC),…

Read MoreCare Access Acquires Brazil-Based Clinical Research Center CEMEC
WAINZUA (Eplontersen) Receives EU Approval for Hereditary ATTR Amyloidosis Treatment
  • Regulatory

WAINZUA (Eplontersen) Receives EU Approval for Hereditary ATTR Amyloidosis Treatment

  • The Pharma Data
  • March 11, 2025

WAINZUA (Eplontersen) Receives EU Approval for Hereditary ATTR Amyloidosis Treatment Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that WAINZUA (eplontersen), developed in collaboration with AstraZeneca, has been approved by the…

Read MoreWAINZUA (Eplontersen) Receives EU Approval for Hereditary ATTR Amyloidosis Treatment
ZYUS Life Sciences Closes Unsecured Loan and Amends Previous Loans
  • News

ZYUS Life Sciences Closes Unsecured Loan and Amends Previous Loans

  • The Pharma Data
  • March 11, 2025

ZYUS Life Sciences Closes Unsecured Loan and Amends Previous Loans ZYUS Life Sciences Corporation (“ZYUS” or the “Company”) (TSX-V: ZYUS), a Canadian-based life sciences company focused on the research, development,…

Read MoreZYUS Life Sciences Closes Unsecured Loan and Amends Previous Loans
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Rule 5635(c)(4)
  • Regulatory

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Rule 5635(c)(4)

  • The Pharma Data
  • March 11, 2025

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company dedicated to discovering, developing, and commercializing innovative therapies for serious and rare…

Read MoreViridian Therapeutics Announces Inducement Grants Under Nasdaq Rule 5635(c)(4)
NeoGenomics Acquires Pathline to Strengthen Oncology Testing in the Northeast
  • Research

NeoGenomics Acquires Pathline to Strengthen Oncology Testing in the Northeast

  • The Pharma Data
  • March 11, 2025

NeoGenomics Acquires Pathline to Strengthen Oncology Testing in the Northeast NeoGenomics, Inc. (“NeoGenomics” or the “Company”) (NASDAQ:NEO), a leading provider of oncology testing services, has announced its acquisition of Pathline,…

Read MoreNeoGenomics Acquires Pathline to Strengthen Oncology Testing in the Northeast
Agomab Reports Positive Interim Phase 2a Results for AGMB-129 in Fibrostenosing Crohn’s Disease
  • Research

Agomab Reports Positive Interim Phase 2a Results for AGMB-129 in Fibrostenosing Crohn’s Disease

  • The Pharma Data
  • March 11, 2025

Agomab Announces Positive Topline Phase 2a Interim Results for AGMB-129 in Fibrostenosing Crohn’s Disease Agomab Therapeutics NV (“Agomab”), a biotechnology company focused on developing innovative treatments for fibrotic diseases, has…

Read MoreAgomab Reports Positive Interim Phase 2a Results for AGMB-129 in Fibrostenosing Crohn’s Disease
Virpax Explores MET Technology for Intranasal COVID-19 Vaccine Development
  • Research

Virpax Explores MET Technology for Intranasal COVID-19 Vaccine Development

  • The Pharma Data
  • March 8, 2025

Virpax Explores MET Technology for Intranasal COVID-19 Vaccine Development Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX) (“Virpax” or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative, non-addictive treatments for pain…

Read MoreVirpax Explores MET Technology for Intranasal COVID-19 Vaccine Development
UroGen Pharma Reports Inducement Grants Under Nasdaq Rule 5635(c)(4)
  • Press Releases

UroGen Pharma Reports Inducement Grants Under Nasdaq Rule 5635(c)(4)

  • The Pharma Data
  • March 8, 2025

UroGen Pharma Reports Inducement Grants Under Nasdaq Rule 5635(c)(4) UroGen Pharma Ltd. (Nasdaq: URGN), a leading biotechnology company focused on developing and commercializing innovative therapies for urothelial and specialty cancers,…

Read MoreUroGen Pharma Reports Inducement Grants Under Nasdaq Rule 5635(c)(4)
NovaBay Pharmaceuticals Announces Special Stockholders Meeting
  • Press Releases

NovaBay Pharmaceuticals Announces Special Stockholders Meeting

  • The Pharma Data
  • March 8, 2025

NovaBay Pharmaceuticals Announces Special Stockholders Meeting NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) (“NovaBay” or the “Company”) has officially announced the scheduling of a virtual Special Meeting on April 16, 2025.…

Read MoreNovaBay Pharmaceuticals Announces Special Stockholders Meeting
PrevNext
UK Biotech Day
Global Clinical Trial Supply Forum 2026 I Frankfurt, Germany

About

The Pharma Data is an Information-Centric Website focused mainly on the Pharmaceutical Industry Online It is a B2B Platform mainly focused on the latest Pharmaceutical News, Press releases, Industry-related updates, Events, and Conferences. With The Pharma Data, you can get all the information that happening in the Pharmaceutical industry.

Advertise With Us: marketing@thepharmadata.com

Latest Posts

  • UCB Expands Immunology Portfolio with Acquisition of Candid Therapeutics, Advancing Novel T-Cell Engager Strategy
  • J&J Statement on FDA Approval of STELARA® for Pediatric Crohn’s Disease
  • Incyte Wins FDA Approval for Jakafi XR™ Extended-Release Tablets Across Multiple Hematologic Indications
  • About Us
  • Disclaimer
  • Privacy Policy
  • Terms and Conditions
  • Contact Us

Copyright © 2026 | The Pharma Data | Marnet Technologies Pvt Ltd | All Rights Reserved.